Evaluating Billing Companies for Allergy Practices
Allergy and immunology billing outsourcing requires a company with three specific competencies that most general medical billing companies lack: high-volume unit-based allergy test coding, long-term immunotherapy patient tracking, and biologic buy-and-bill expertise. A billing company that handles primary care or general internal medicine well may struggle with the procedural complexity and multi-year patient management that allergy billing demands. Testing the company on these three competencies before signing a contract prevents costly mistakes during the first year.
Criteria 1: Allergy Coding Knowledge
Test the billing company knowledge of allergy-specific coding by asking concrete questions. What is the difference between 95004 and 95024? How do you bill a session with 45 percutaneous tests and 15 intradermal tests? When do you use 95115 versus 95117? How do you bill controls on a testing panel? A company that cannot answer these questions accurately will undercode testing visits and lose revenue from the first week.
Ask for their experience with allergy testing claim denials. Can they identify the most common denial reasons (test frequency limits, panel size caps, medical necessity)? Do they know how to structure appeals for testing denials? Allergy testing denial rates directly correlate with the billing company expertise in this area.
Criteria 2: Immunotherapy Tracking Capabilities
Immunotherapy billing requires patient-level tracking across months or years. The billing company must track which patients are in build-up versus maintenance, monitor visit compliance, capture vial preparation charges (95165) when new vials are mixed, and flag patients approaching payer visit limits. Ask the company to demonstrate their immunotherapy tracking system. If they rely on manual processes or basic spreadsheets, they will miss charges and fail to catch compliance issues at scale.
Evaluate how they handle the transition from build-up to maintenance billing. During build-up, patients visit weekly and generate higher total revenue. During maintenance, visits decrease to monthly, and the billing company must adjust expectations and flag any missed appointments that could affect treatment efficacy and revenue.
Criteria 3: Biologic Buy-and-Bill Expertise
If the practice administers biologics (omalizumab, dupilumab, mepolizumab), the billing company must manage prior authorization tracking, drug billing with correct J-codes and units, administration code selection, and drug margin reconciliation. Ask whether they track PA expiration dates and initiate renewals proactively. Ask how they verify that drug reimbursement covers acquisition cost plus margin. A billing company that treats biologics like standard injections will miss PA renewals and fail to identify underpayments on drug claims.
Criteria 4: Pricing Models for Allergy
Allergy billing outsourcing pricing ranges from 5% to 9% of collections. The wide range reflects the complexity: practices with heavy testing and biologic programs require more billing work per encounter than injection-only practices. Per-claim pricing ($4 to $8 per claim) may be more economical for practices with high immunotherapy injection volume, since injection claims are simple but frequent.
Evaluate total annual cost by modeling your specific volume: the number of testing encounters per month, immunotherapy injection visits per month, biologic administrations per month, and standard E/M visits per month. Apply each candidate pricing model to this volume and compare the annual cost. The lowest percentage rate is not always the lowest total cost.
Criteria 5: Reporting Requirements
Require allergy-specific reports: testing revenue per encounter, immunotherapy patient count and revenue by phase (build-up vs. maintenance), biologic drug margin by payer, denial rate by claim category (testing, injections, drugs), and vial preparation charge capture. Standard reporting packages designed for primary care or surgical practices do not capture the allergy-specific metrics that drive financial performance.
Red Flags
Avoid billing companies that have no allergy practice clients, cannot distinguish between percutaneous and intradermal test coding, have no system for tracking immunotherapy patients over multi-year treatment courses, or are unfamiliar with biologic buy-and-bill workflows. Also avoid companies that quote a flat percentage without understanding your service mix, as allergy billing complexity varies significantly based on the proportion of testing, immunotherapy, and biologic services.